Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 745, Issue -, Pages 243-248Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejphar.2014.10.043
Keywords
alpha-synaclein; Methamphetamine; DNA methylation; Methyl CpG binding protein 2; DNA methyltransferase 1
Categories
Ask authors/readers for more resources
Abuse of methamphetamine (METH) increases the risk of occurrence of Parkinson's disease (PD) in the individuals. Increased expression of synaptic protein (i-synuclein (encoded by gene Sum) is remarkably associated with the neuronal loss and motor dysfunction in the patients with PD. The present study aimed to explore the epigenetic mechanism underlying the altered expression of alpha-synuclein in substantia nigra in the rats previously exposed to METH. Exposure to METH induced significant behavioral impairments in the rotarod test and open field test, as well as the upregulation of cytokine synthesis in the substantia nigra. Significantly increased expression of alpha-synuclein was also observed in the substantia nigra in the rats exposed to METH. Further chromatin immunoprecipitation and bisulfite sequencing studies revealed a significantly decreased cytosine methylation in the Snca promoter region in the rats exposed to METH. It was found that the occupancy of methyl CpG binding protein 2 and DNA methyltransferase 1 in Slim promoter region was also significantly decreased in the substantia nigra in the modeled rats. These results advanced our understanding on the mechanism of the increased incidence of PD in the individuals with history use of METH, and shed novel lights on the development of therapeutic approaches for the patients conflicted with this neurological disorder. (C) 2014 Elsevier BA/. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available